Calculus Capital News Today

With some saying that the government’s focus on UK investment has brought a renewed sense of optimism and stability to the tax-efficient investment space, Isabel Baxter explores if advisers need to utilise these schemes more…

STEVENAGE, United Kingdom, March 26, 2024 (GLOBE NEWSWIRE) -- Laverock Therapeutics, a gene-silencing company with a uniquely powerful technolog...

Laverock Therapeutics, which is growing fast from its base at Stevenage Bioscience Catalyst, has unveiled Ali Elsley as Finance Director and revealed significant expansion of its team.

MIP Discovery, a developer of non-biological affinity reagents designed to accelerate the production of cell and gene therapies, has closed a £7 million Series A financing round, led by Mercia Ventures.

FinSMEs is the financial news site dedicated to covering venture capital, private equity, and merger and acquisition deals in real time!

Tagomics, a trailblazing developer of a state-of-the-art platform for comprehensive disease insight and diagnosis, has announced a successful £6.7 million funding round.

The University of Birmingham spin-out is working to advance cancer treatment

Bedfordshire-based MIP Discovery, which develops non-biological affinity reagents to accelerate development and production of cell and gene therapies, has closed a £7 million ($9m) Series A. The round was led by Mercia Ventures. Existing investor Calculus Capital also participated along with angel backers.

FinSMEs is the financial news site dedicated to covering venture capital, private equity, and merger and acquisition deals in real time!

A higher for longer interest rates environment is poised to weigh on the growth and performance of the private markets industry.